Single-AAV-mediated cardiomyocyte-specific adenine base editing ameliorates cardiac hypertrophy in vivo

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, frequently accompanied by cardiac hypercontractility, diastolic dysfunction, heart failure and sudden cardiac death. The disease is predominantly caused by pathogenic variants in genes encoding sarcomeric proteins and current therapeutic strategies largely focus on symptom management. Adeno-associated virus-based (AAV) delivery of base editing tools has emerged as an alternative strategy that acts directly on the genetic cause of disease. However, canonical SpCas9-based editors are too large to package into a single-AAV vector which mandates dual-AAV approaches that require higher overall vector doses with elevated toxicity risk and increased manufacturing costs. Here, we report the development and application of a single vector approach for cardiomyocyte-specific adenine base editing to correct a Dutch founder mutation in MYBPC3 (c.2827C>T, p.Arg943Ter) that causes HCM. We systematically compared compact base editors in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and selected the most efficient configuration, which reversed disease-associated hypercontractility in engineered human myocardium (EHM). To fit the editor/guide construct in a single-AAV vector, we screened a library of rationally designed small chimeric promoters and identified 6C2 to effectively drive expression in hiPSC-CMs and cardiac tissue of both mice and non-human primates (NHP) with exceptional specificity. Delivered in a single next-generation cardiotropic AAV capsid, we achieved therapeutic correction in an HCM mouse model at doses 20-fold below published dual-AAV cardiomyopathy base editing approaches. These results establish cardiomyocyte-specific, single vector-mediated base editing as a viable therapeutic strategy for inherited cardiomyopathies.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-13
DOI
https://doi.org/10.64898/2026.11.12.765297
Primary Topic
Virus-based gene therapy research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Single-AAV-mediated cardiomyocyte-specific adenine base editing ameliorates cardiac hypertrophy in vivo

Kathryn N. Ivey, Prasad R. Konkalmatt, Danny D. Sahtoe, Cornelis J.J. Boogerd et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Virus-based gene therapy research
preprint

Single-AAV-mediated cardiomyocyte-specific adenine base editing ameliorates cardiac hypertrophy in vivo

Kathryn N. Ivey, Prasad R. Konkalmatt, Danny D. Sahtoe, Cornelis J.J. Boogerd, Sebastiaan J. van Kampen, Mauro Giacca, Maya Wright Clark, Serj Koshian, Daniëlle Versteeg, Hesther de Ruiter, Eva van Rooij, Christopher A. Reid, Martijn Wehrens, Mohammad A. Mandegar, Lorena Zentilin, Ilaria Perini, Thomas Monnikhof, Ceren Agirman, Su Ji Han, Anne E. de Leeuw, Laura Stumpo, Alessandra Luppino, Tessa Wigman, Margot Chevalier
preprint en

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, frequently accompanied by cardiac hypercontractility, diastolic dysfunction, heart failure and sudden cardiac death. The disease is predominantly caused by pathogenic variants in genes encoding sarcomeric proteins and current therapeutic strategies largely focus on symptom management. Adeno-associated virus-based (AAV) delivery of base editing tools has emerged as an alternative strategy that acts directly on the genetic cause of disease. However, canonical SpCas9-based editors are too large to package into a single-AAV vector which mandates dual-AAV approaches that require higher overall vector doses with elevated toxicity risk and increased manufacturing costs. Here, we report the development and application of a single vector approach for cardiomyocyte-specific adenine base editing to correct a Dutch founder mutation in MYBPC3 (c.2827C>T, p.Arg943Ter) that causes HCM. We systematically compared compact base editors in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and selected the most efficient configuration, which reversed disease-associated hypercontractility in engineered human myocardium (EHM). To fit the editor/guide construct in a single-AAV vector, we screened a library of rationally designed small chimeric promoters and identified 6C2 to effectively drive expression in hiPSC-CMs and cardiac tissue of both mice and non-human primates (NHP) with exceptional specificity. Delivered in a single next-generation cardiotropic AAV capsid, we achieved therapeutic correction in an HCM mouse model at doses 20-fold below published dual-AAV cardiomyopathy base editing approaches. These results establish cardiomyocyte-specific, single vector-mediated base editing as a viable therapeutic strategy for inherited cardiomyopathies.

bioRxiv (Cold Spring Harbor Laboratory)
Royal Netherlands Academy of Arts and Sciences (NL), King's College London (GB), The Netherlands Cancer Institute (NL), University Medical Center Utrecht (NL), International Centre for Genetic Engineering and Biotechnology (ZA), Oncode Institute (NL), Hubrecht Institute for Developmental Biology and Stem Cell Research (NL), International Centre for Genetic Engineering and Biotechnology (IN)
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon